Targeted cancer therapy (original) (raw)

• Sawyers, C. L. Opportunities and challenges in the development of kinase inhibitor therapy for cancer. Genes Dev. 17, 2998–3010 (2003).
  Article CAS PubMed Google Scholar
• Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497–1500 (2004).
  Article ADS CAS PubMed Google Scholar
• Sordella, R., Bell, D. W., Haber, D. A. & Settleman, J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305, 1163–1167 (2004).
  Article ADS CAS PubMed Google Scholar
• Stephens, P. et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 431, 525–526 (2004).
  Article ADS CAS PubMed Google Scholar
• Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949–954 (2002).
  Article ADS CAS PubMed Google Scholar
• Bardelli, A. et al. Mutational analysis of the tyrosine kinome in colorectal cancers. Science 300, 949–950 (2003).
  Article CAS PubMed Google Scholar
• Samuels, Y. et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554 (2004).
  Article CAS PubMed Google Scholar
• Cools, J. et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. 348, 1201–1214 (2003).
  Article CAS PubMed Google Scholar
• Rubin, B. P. et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J. Clin. Oncol. 20, 3586–3591 (2002).
  Article CAS PubMed Google Scholar
• De Angelo, D. J. et al. Phase I clinical results with MLN518, a novel FLT3 antagonist: tolerability, pharmacokinetics, and pharmacodynamics. Blood 102 (65a), Abstr. 219 (2003).
  Google Scholar
• Stone, R. M. et al. Oral PKC 412 has activity in patients (pts) with mutant FLT3 acute myeloid leukemia (AML): a phase II trial. Proc. Am. Soc. Clin. Oncol. Abstr. 22, 563 (2003).
  Google Scholar
• Smith, B. D. et al., Single agent CEP-701, a novel FLT3 inhibitor, shows initial response in patients with refractory acute myeloid leukemia. Proc. Am. Soc. Clin. Oncol. Abstr. 22, 194 (2003).
  Google Scholar
• Gorre, M. E. et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876–880 (2001).
  Article CAS PubMed Google Scholar
• Shah, N. P. et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2, 117–125 (2002).
  Article CAS PubMed Google Scholar
• Branford, S. et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99, 3472–3475 (2002).
  Article CAS PubMed Google Scholar
• Shah, N. P. et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305, 399–401 (2004).
  Article ADS CAS PubMed Google Scholar
• Romer, J. T. et al. Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/−)p53(−/−) mice. Cancer Cell 6, 229–240 (2004).
  Article CAS PubMed Google Scholar
• Wolfel, T. et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269, 1281–1284 (1995).
  Article ADS CAS PubMed Google Scholar
• Williams, M. E., Swerdlow, S. H. & Meeker, T. C. Chromosome t(11;14)(q13;q32) breakpoints in centrocytic lymphoma are highly localized at the bcl-1 major translocation cluster. Leukemia 7, 1437–1440 (1993).
  CAS PubMed Google Scholar
• Sawyers, C. L. Will mTOR inhibitors make it as cancer drugs? Cancer Cell 4, 343–348 (2003).
  Article CAS PubMed Google Scholar
• Hughes, T. P. et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 349, 1423–1432 (2003).
  Article CAS PubMed Google Scholar
• Graham, S. M. et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99, 319–325 (2002).
  Article CAS PubMed Google Scholar
• Bhatia, R. et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 101, 4701–4707 (2003).
  Article CAS PubMed Google Scholar
• Chu, S. et al. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood published online 2 September 2004 (doi: 10.1182/blood-2004-03-1114).
• Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335–2342 (2004).
  Article CAS PubMed Google Scholar
• Yang, J. C. et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349, 427–434 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Ratain et al. ASCO annual meeting proceedings (post-meeting edn). J. Clin. Oncol. 22, (no. 14 suppl.) 4501 (2004).
  Article Google Scholar
• Motzer et al. ASCO annual meeting proceedings (post-meeting edn). J. Clin. Oncol. 22, (no. 14 suppl.) 4500 (2004).
  Article Google Scholar
• Kaelin, W. G., Jr Molecular basis of the VHL hereditary cancer syndrome. Nature Rev. Cancer 2, 673–682 (2002).
  Article CAS Google Scholar
• Bhowmick, N. A. et al. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303, 848–851 (2004).
  Article ADS CAS PubMed Google Scholar
• Olumi, A. F. et al. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 59, 5002–5011 (1999).
  CAS PubMed Google Scholar